NICE Recommends Evenity for Patients With Severe Osteoporosis

The UK’S National Institute for Health and Care Excellence (NICE) has recommended Amgen’s Evenity (romosozumab) for use by the National Health Service (NHS) for the treatment of postmenopausal patients with severe osteoporosis who are at high risk of fracture.

NICE previously rejected the sclerostin inhibitor in November 2021 because it did not consider the drug cost-effective for NHS use. But the institute reconsidered based on new clinical trial data indicating that Evenity followed by alendronic acid is more effective at reducing the risk of fractures compared with alendronic acid alone.

The list price for two Evenity pre-filled pens, which are administered as single monthly doses, was approximately $560 per dose in October 2021. NICE did not disclose the price it negotiated with the company for use by the NHS.